<DOC>
	<DOCNO>NCT00958997</DOCNO>
	<brief_summary>Pancreatic Islet beta-cells responsible synthesize secrete appropriate amount insulin regulate blood glucose level . One factor development diabetes loss beta-cells . Developing treatment prevent restore islet beta-cell mass ( BCM ) diabetic patient hamper lack method non-invasive image cell . This study design evaluate radiolabeled compound bind pancreatic islet . The investigator test ability one promising image compound , 18F-9-fluoropropyl- ( + ) -dihydrotetrabenazine ( 18F-FP-DTBZ ) , measure amount pancreatic islet beta-cells patient long-standing type-1 diabetes age-weight-matched healthy control subject .</brief_summary>
	<brief_title>Positron Emission Tomography ( PET ) Imaging Pancreatic Beta-Cell Mass Healthy Type 1 Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>1 . Patients Type 1 diabetes may enrol meet follow criterion : Have diagnosis Type 1 diabetes mellitus define ADA criterion judgment physician ; diabetes onset young age 18 , duration &gt; 5 year Have fast CPeptide ≤ 0.1 ng/ml BMI 18 29 kg/m2 Able tolerate PET MR image No metal implant No claustrophobia 2 . Healthy volunteer may enrol meeting follow criterion : Have history Type 1 diabetes Fasting blood glucose ≤ 100 mg/dL Negative islet autoantibody test BMI 18 29 kg/m2 Able tolerate PET MR image No history previous allergic reaction drug No metal implant No claustrophobia Clinically significant renal dysfunction ; Clinically significant liver dysfunction determine history , physical examination , standard liver function test screening ( AST , ALT , Total/Direct Bilirubin , Alkaline Phosphatase ) ; Coagulopathy ; History allergic reaction drug Current use medication except insulin Type 1 diabetes Clinically significant cardiovascular disease clinically significant abnormality screen ECG ( include limit QTc &gt; 450 msec ) ; Clinically significant psychiatric disease ; Clinically significant pulmonary , renal hepatic impairment cancer , clinically significant infectious disease , include AIDS HIV infection , previous positive test hepatitis B , hepatitis C , HIV1 , HIV2 ; subject ask . No test perform . Have history alcohol substance abuse dependence ; Are woman childbearing potential refrain sexual activity use adequate contraception . Women must pregnant ( negative serum βHCG time screen ) lactate screening , must agree take appropriate step become pregnant study 30 day follow study . Currently receive investigational medication , participate trial investigational medication within last 30 day . Have receive diagnostic therapeutic radiopharmaceutical within 7 day prior participation study . Claustrophobia Metal implant ( pacemaker , artificial joint , nonremovable body piercings )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>diabetes</keyword>
	<keyword>islet</keyword>
	<keyword>pancreas</keyword>
	<keyword>beta cell mass</keyword>
	<keyword>PET image</keyword>
	<keyword>FPDTBZ</keyword>
	<keyword>arginine stimulus test</keyword>
</DOC>